Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
Evidence dashboardStudies since 2000Updated Jul 31, 2026

LanreotideClinical Trials.

A source-linked view of every Lanreotide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.

Total trials
75
Recruiting
7
Completed
43
Terminated
13
Results posted
28
Average enrollment
74
Countries
44
Highest phase
Phase 4

Largest indexed study

1,965 participants · NCT03158090 →

Developer / research origin

Ipsen

Evidence summary

Activity is not efficacy.

Lanreotide appears in 75 indexed studies: 7 recruiting, 43 completed and 28 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Lanreotide is safe or effective.

Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.

Development history

Trial timeline.

Evidence timeline

2000—2026

200020002003200420042004200520062006200720082008200920092010201120122013

Velocity

Lanreotide studies by start year

Study start year · indexed snapshot

8642020002000: 2 trials2001: 0 trials2002: 0 trials2003: 2 trials2004: 3 trials20052005: 1 trials2006: 4 trials2007: 1 trials2008: 4 trials2009: 2 trials20102010: 2 trials2011: 1 trials2012: 1 trials2013: 1 trials2014: 3 trials20152015: 5 trials2016: 7 trials2017: 8 trials2018: 2 trials2019: 5 trials20202020: 5 trials2021: 5 trials2022: 4 trials2023: 3 trials2024: 0 trials20252025: 3 trials20262026: 1 trials

Development

Trials by phase

Early Phase 11
Phase 14
Phase 223
Phase 323
Phase 49

Current studies

Recruiting or active

Completed studies

Finished records

Stopped studies

Withdrawn or terminated

Showing 6 of 10 studies
Showing 6 of 43 studies
Showing 6 of 17 studies

Full study index

Search Lanreotide trials.

Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.

75 matching studies

Latest publications

Follow the paper trail.

PMID 38229199 ↗Singh S, Ferone D, Capdevila J, Chan JA, de Herder WW, Halperin D, Mailman J, Hellstrom L, Liedman H, Svedberg A, Tiberg F. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. Trials. 2024 Jan 16;25(1):58. doi: 10.1186/s13063-023-07834-8.Linked from NCT05050942PMID 42320793 ↗Joly D, Ursino M, Bienaime F, El Karoui K, Karras A, Thervet E, Boffa JJ, Galichon P, Luque Y, Michel PA, Cartery C, Vrtovsnik F, Daugas E, Peraldi MN, Colas S, Semeraro M, Treluyer JM, Meyzer C, Hummel A, Fouchard M, Nguyen-Khoa T, Knebelmann B, Alberti C. A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease. Kidney Int. 2026 Jun 19:S0085-2538(26)00498-9. doi: 10.1016/j.kint.2026.05.018. Online ahead of print.Linked from NCT02127437PMID 39356039 ↗St Pierre K, Cashmore BA, Bolignano D, Zoccali C, Ruospo M, Craig JC, Strippoli GF, Mallett AJ, Green SC, Tunnicliffe DJ. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3.Linked from NCT02127437PMID 38753757 ↗Taunk NK, Escorcia FE, Lewis JS, Bodei L. Radiopharmaceuticals for Cancer Diagnosis and Therapy: New Targets, New Therapies-Alpha-Emitters, Novel Targets. Cancer J. 2024 May-Jun 01;30(3):218-223. doi: 10.1097/PPO.0000000000000720.Linked from NCT05477576PMID 35724357 ↗Raj N, Cruz E, O'Shaughnessy S, Calderon C, Chou JF, Capanu M, Heffernan O, DeMore A, Punn S, Le T, Hauser H, Saltz L, Reidy-Lagunes D. A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors. JCO Oncol Pract. 2022 Sep;18(9):e1533-e1541. doi: 10.1200/OP.22.00055. Epub 2022 Jun 20.Linked from NCT03289741PMID 36792844 ↗Martin S, Bender RH, Krasner A, Marmon T, Monahan M, Nelson L. Development and evaluation of the Acromegaly Symptom Diary. J Patient Rep Outcomes. 2023 Feb 15;7(1):15. doi: 10.1186/s41687-023-00541-7.Linked from NCT03792555PMID 25014687 ↗Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158.Linked from NCT00353496PMID 33052555 ↗Caplin ME, Pavel M, Phan AT, Cwikla JB, Sedlackova E, Thanh XT, Wolin EM, Ruszniewski P; CLARINET Investigators. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021 Feb;71(2):502-513. doi: 10.1007/s12020-020-02475-2. Epub 2020 Oct 14.Linked from NCT00353496

Related pages

Keep researching Lanreotide.

Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.

DatabaseLanreotide database page →Research guideRead the Lanreotide guide →Lab reportsSearch the COA ledger →Source registrySearch ClinicalTrials.gov ↗